logo
Plus   Neg
Share
Email

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After coming under pressure early in the session, stocks regained some ground over the course of the trading day on Friday. The major averages climbed well off their lows of the session, with the S&P 500 briefly turning positive. President Donald Trump's former campaign chairman Paul Manafort is headed to jail after his bail was revoked by a District Court Judge on Friday. Manafort will remain in jail as he awaits trial on criminal charges related to his lobbying work for a pro-Russia party in Ukraine. Dealing a major blow to House Republican leaders that spent weeks crafting compromise immigration legislation, President Donald Trump declared Friday that he will not sign the bill. The comments from Trump come after House Speaker Paul Ryan, R-Wis., staved off a revolt by some moderate Republicans...
Follow RTT